The largest database of trusted experimental protocols

13 protocols using isoguvacine

1

Extracellular Recordings of Hippocampal Slices

Check if the same lab product or an alternative is used in the 5 most similar protocols
Extracellular field recordings were performed in the CA3 pyramidal layer of hippocampal slices of P16 mice with glass pipettes (Harvard Apparatus, MA, USA) containing ACSF. Spike frequency was recorded for 10 min (control period), then isoguvacine (10 μM; Sigma-Aldrich, MO, USA) was applied in the bath solution for 90 s (isoguvacine period). Following isoguvacine application, spike frequency was recorded for an extra 15 min (wash-out period). Signals were recorded with a low-noise multichannel DAM-80A amplifier (WPI, UK; low-pass filter 1 Hz; high-pass filter 3 kHz; gain ×1000) and digitized online with a Digidata 1400A digitizer (Molecular Devices, CA, USA). Recordings were analyzed using Clampfit 10.4 software (Molecular Devices, CA, USA). The spike detection threshold was defined as three times the standard deviation of the noise recorded in the bath solution. Spike frequency was calculated for control, isoguvacine, and wash-out periods. Slices for which wash-out spike frequency did not come back to control levels (±20% of control) were excluded from this study.
+ Open protocol
+ Expand
2

GABAA Agonist Microinjections to Inhibit Kölliker-Fuse Nucleus

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bilateral microinjections of isoguvacine (a GABAA agonist, 10 mM, Sigma–Aldrich) containing 5% fluorescent latex microbeads (Lumafluor, New City, NY, USA) were performed into the KF to pharmacologically inhibit this region. Before the isoguvacine microinjections, the KF was functionally identified by microinjections of L-glutamate (10 mM, Sigma–Aldrich), which evoked an increase in cVN post-I activity and PN apnea (Bautista and Dutschmann, 2014 (link)), as demonstrated in Fig. 1. The glass pipettes contained either the drug-microbead mixture or L-glutamate and were positioned in the KF using the following stereotaxic coordinates: 5.5 mm rostral from the calamus scriptorius; 1.75 mm lateral from midline; and 1.5 mm ventral to the dorsal surface. The volume of each microinjection was 70–90 nL. Despite the accuracy of the bilateral injections (as observed with both the histology and the consistent reduction in the cVN post-inspiratory peak), these injections may have not necessarily inhibited all KF neurons.
+ Open protocol
+ Expand
3

Expressing and Analyzing GABA-ρ Receptors

Check if the same lab product or an alternative is used in the 5 most similar protocols
The subcloned human GABA-ρ1 cDNA into pcDNA1.1 (Invitrogen, San Diego, CA, USA) was generously donated by Dr. George Uh1 (National Institute for Drug Abuse, Baltimore, MD, USA). The subcloned human GABA-ρ2 cDNA into PKS (Invitrogen) was generously provided by Dr. Garry Cutting (Center for Medical Genetics, Johns Hopkins University School of Medicine, Baltimore, MD, USA).
GABA, muscimol, β-alanine, 5-amino valeric acid, glycine, isoguvacine, and imidazole-4-acetic acid were purchased from Sigma-Aldrich (Sigma-Aldrich Pty Ltd., Castle Hill, NSW 1765, Australia). TACA and CACA were prepared as previously reported [3 (link)].
+ Open protocol
+ Expand
4

Pharmacological Modulation of Neuronal Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
For in vitro experiments, SR 95531 hydrobromide (gabazine 5 μM, Tocris Bioscience, UK, Ref. 1262), NMDA (10 μM, Tocris Bioscience, UK, Ref. 0114), 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione (10 µM, NIH generous gift), GABA (10 μM, Sigma-Aldrich), isoguvacine (10 μM, Sigma-Aldrich, Ref. G002), DL -2-Amino-5-phosphonovaleric acid (40 µM, Sigma-Aldrich, Ref. A5282), and bumetanide (10 μM, Sigma-Aldrich, Ref. B3023) were directly added to the perfusion solutions. For ca experiments, slices were treated with bumetanide for 40 min before and during recordings. Cocktail of nicotinic receptor antagonists included mecamylamine hydrochloride (10 μM, Tocris Bioscience, Ref. 2843/10), methyllycaconitine citrate (0.1 μM, Tocris Bioscience, Ref. 1029/5), and dihydro-β-erythroidine hydrobromide (10 μM, Tocris Bioscience, Ref. 2349/10). For in vivo experiments, bumetanide pretreatment (3 mg kg−1) was given to mice in drinking water during 5 weeks.
+ Open protocol
+ Expand
5

Extracellular Recording of Hippocampal Slices

Check if the same lab product or an alternative is used in the 5 most similar protocols
Hippocampal slices are individually transferred to a recording chamber maintained at 30–32°C and continuously perfused (2 mL/min) with oxygenated normal or adapted ACSF. Extracellular field recordings are made using tungsten wire electrodes (diameter: 50 μm, California Fine Wire, Grover Beach, CA, United States). Recording electrodes are positioned in a pyramidal cell layer of CA3 subfield, and signals are amplified using custom- DAM-8A amplifiers (WPI, GB; low-pass filter: 0.1 Hz; high-pass filter: 3 kHz; gain: x1000) and then acquired using an A/D converter (Digidata 1440A, Axon Instruments). Clampfit 10.1 (Axon Instruments) software is used for the acquisition and analysis of the network activity. Isoguvacine and bumetanide are purchased from Sigma.
+ Open protocol
+ Expand
6

Recombinant Expression of Human GABA Receptor

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human ρ1 cDNA subcloned into pcDNA1.1 (Invitrogen, San Diego, CA, USA) was kindly provided by Dr. George Uh1 (National Institute for Drug Abuse, Baltimore, MD, USA).
(GABA, 5-aminovaleric acid, β-alanine, glycine, isoguvacine, 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol (THIP) also known as Gaboxadol, were purchased from Sigma-Aldrich (Sigm-Aldrich Pty Ltd, Castle Hill, NSW 1765 Australia). 1,2,5,6-Tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA) [31 (link)], trans-aminocrotonic acid (TACA) and cis-aminocrotonic acid (CACA) [32 (link)], and 2-aminoethylmethane thiosulfonate (MTSEA) [33 (link)] were prepared as previously reported.
+ Open protocol
+ Expand
7

Modulating Chloride Homeostasis and GABA Signaling in Ischemic Injury

Check if the same lab product or an alternative is used in the 5 most similar protocols
Treatments were applied either during the 2 h exposure to OGD/sham normoxia (T1) or post-exposure, during the 3 h necessary for viability assessment (T2).
We blocked outward Cl transport with DIOA, a KCC2 blocker (Sigma, 20 µM), and inward Cl transport with bumetanide (Sigma, 10 µM), a NKCC1 blocker as a means for increasing, respectively decreasing [Cl]i either during OGD (T1) or post-exposure (T2). We also used the GABAA receptor antagonist gabazine (Sigma, 30 µM) as well as the GABAA receptor agonist isoguvacine (Sigma, 40 µM) to modulate the GABAA channel, both during OGD (T1) and during post-exposure (T2). All treatments were also applied to normoxic cultures. Experimental design and treatment times are illustrated in Figure 1.
+ Open protocol
+ Expand
8

Pharmacological Modulation of GABAergic Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols
In vitro. Bumetanide (10 μM, Sigma-Aldrich, MO, USA), isoguvacine (10 μM, Sigma-Aldrich, MO, USA), TTX (1 μM, Abcam, Bristol, UK), CNQX (10 μM, Sigma-Aldrich, MO, USA), gabazine (5 μM, Tocris Cookson, Bristol, UK) and DHPG (50 μM, Tocris Bioscience, UK) were directly added to the perfusion solutions.
In vivo. Pregnant mice were randomly assigned for Bumetanide pretreatment (2.5 mg/kg) administered in the drinking water.
+ Open protocol
+ Expand
9

Neurotransmitter Modulation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Isoguvacine, baclofen, gabazine, CGP-35348 and vigabatrin were obtained from Sigma Chemical Co. All these chemicals were dissolved in normal saline.
+ Open protocol
+ Expand
10

Drugs Application in Neuronal Bath

Check if the same lab product or an alternative is used in the 5 most similar protocols
Drugs were applied in the bath via a three-way tap system, by changing the superfusion solution to one differing only in its content of drug(s). Drugs used were: SR 95531 hydrobromide (gabazine), DNQX and picrotoxin purchased from Ascent Scientific (UK), isoguvacine from Sigma-Aldrich (Italy) and TTX from Latoxan (Israel). Stock solutions were made in distilled water and then aliquoted and frozen at −20 °C. DNQX was dissolved in DMSO. The final concentration of DMSO in the bathing solution was 0.1%. At this concentration, DMSO alone did not modify the membrane potential, input resistance or the firing properties of neurons.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!